Logo Image

James J. Harding, MD

Articles by James J. Harding, MD

Experts featured in this series.

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

ByRachna T. Shroff, MD, MS, FASCO,James J. Harding, MD,Lipika Goyal, MD,Midhun Malla, MD,Ronan W. Hsieh, MD,Zahra Hamedi, MD,Jun Gong, MD

In the second clinical scenario of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), Team Chicago Hot Dog manages a 54-year-old man with NASH-related cirrhosis and BCLC stage C disease, excellent performance status, bulky bilobar disease with a 9.2-cm dominant lesion, Vp3 invasion, two lung metastases, Child-Pugh A5, ALBI grade 1, no varices on recent endoscopy, and a rapidly rising alpha-fetoprotein level.

Experts featured in this series.

Managing Multifocal BCLC-C HCC With Portal Vein Invasion and Variceal History

ByRachna T. Shroff, MD, MS, FASCO,James J. Harding, MD,Lipika Goyal, MD,Midhun Malla, MD,Ronan W. Hsieh, MD,Zahra Hamedi, MD,Jun Gong, MD

In the first clinical scenario of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), Team Deep-Dish Pizza manages a 67-year-old woman with hepatitis B cirrhosis and BCLC stage C disease, multifocal bilobar tumors with branch portal vein invasion (Vp3), Child-Pugh A6, ALBI grade 2, and an elevated alpha-fetoprotein level.

Experts featured in this series.

Debating Locoregional Versus Earlier Systemic Therapy in BCLC-B HCC

ByRachna T. Shroff, MD, MS, FASCO,James J. Harding, MD,Lipika Goyal, MD,Midhun Malla, MD,Ronan W. Hsieh, MD,Zahra Hamedi, MD,Jun Gong, MD

In the third debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a Child-Pugh A, BCLC stage B patient eligible for locoregional therapy, asking whether clinicians should prioritize locoregional treatment or introduce systemic therapy earlier.

Experts featured in this series.

Debating Frontline Treatment for Child-Pugh B7 Disease With Compromised Liver Function

ByRachna T. Shroff, MD, MS, FASCO,James J. Harding, MD,Lipika Goyal, MD,Midhun Malla, MD,Ronan W. Hsieh, MD,Zahra Hamedi, MD,Jun Gong, MD

In the second debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a treatment-naive patient with Child-Pugh B7, BCLC stage C disease and compromised liver function, asking how limited liver reserve should influence frontline selection.

Experts featured in this series.

Reviewing the EMERALD-1 Trial of TACE With Durvalumab and Bevacizumab

ByRachna T. Shroff, MD, MS, FASCO,James J. Harding, MD,Lipika Goyal, MD,Midhun Malla, MD,Ronan W. Hsieh, MD,Zahra Hamedi, MD,Jun Gong, MD

Jun Gong, MD, presents the EMERALD-1 trial for Team Chicago Hot Dog, reviewing the phase 3, randomized, double-blind study of transarterial chemoembolization (TACE) with durvalumab, with or without bevacizumab, in unresectable hepatocellular carcinoma (HCC) amenable to embolization.

Latest Updated Articles